{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:55:08Z","timestamp":1784696108283,"version":"3.55.0"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0120705","type":"journal-article","created":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T12:44:14Z","timestamp":1427805854000},"page":"e0120705","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir\/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00872417","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","article-title":"Five-year outcomes of the China National Free Antiretroviral Treatment Program","volume":"151","author":"F Zhang","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref2","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. 2010."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/649884","article-title":"Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India","volume":"50","author":"MA Bender","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e64459","DOI":"10.1371\/journal.pone.0064459","article-title":"Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study","volume":"8","author":"K Velen","year":"2013","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1471-2334-13-301","article-title":"Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study","volume":"13","author":"Y Cao","year":"2013","journal-title":"BMC Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/QAD.0000000000000125","article-title":"CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission","volume":"28","author":"Y Li","year":"2014","journal-title":"AIDS"},{"key":"ref7","article-title":"HIV-1 subtype B\/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China","author":"Y Li","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"TF Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/QAI.0b013e31826a6c4f","article-title":"Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals","volume":"61","author":"LA Inker","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/cid\/ciu355","article-title":"Renal function of participants in the Bangkok tenofovir study-Thailand, 2005\u20132012","volume":"59","author":"M Martin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"DE Bennett","year":"2009","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/infdis\/jiu333","article-title":"HIV Reverse-Transcriptase Drug Resistance Mutations During Early Infection Reveal Greater Transmission Diversity Than in Envelope Sequences","volume":"210","author":"JT Lipscomb","year":"2014","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1089\/aid.2009.0252","article-title":"Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces","volume":"26","author":"L Ma","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-2652-14-14","article-title":"High efficacy of lopinavir\/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER\/Calmette Hospital in Phnom Penh, Cambodia","volume":"14","author":"L Ferradini","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e3918","DOI":"10.1371\/journal.pone.0003918","article-title":"Three generic nevirapine-based antiretroviral treatments in Chinese HIV\/AIDS patients: multicentric observation cohort","volume":"3","author":"T Li","year":"2008","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3760\/cma.j.issn.0366-6999.20132557","article-title":"An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China","volume":"127","author":"T Li","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1586\/ecp.12.45","article-title":"Safety of pharmacoenhancers for HIV therapy","volume":"5","author":"N von Hentig","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e3282f4243b","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV","volume":"22","author":"F Pulido","year":"2008","journal-title":"AIDS"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/01.aids.0000161777.38438.ed","article-title":"Lopinavir\/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients","volume":"19","author":"RE Campo","year":"2005","journal-title":"AIDS"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/QAD.0b013e32831c54e5","article-title":"HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review","volume":"23","author":"WF Bierman","year":"2009","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e29977","DOI":"10.1371\/journal.pone.0029977","article-title":"Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naive patients with HIV infection","volume":"7","author":"T Nishijima","year":"2012","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/428840","article-title":"Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment","volume":"40","author":"JE Gallant","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0000000000000156","article-title":"Changes in renal function associated with oral emtricitabine\/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis","volume":"28","author":"MM Solomon","year":"2014","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32832c96e9","article-title":"Renal function with use of a tenofovir-containing initial antiretroviral regimen","volume":"23","author":"JE Gallant","year":"2009","journal-title":"AIDS"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283112b8e","article-title":"The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients","volume":"22","author":"JE Gallant","year":"2008","journal-title":"AIDS"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1053\/j.ajkd.2011.10.050","article-title":"Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors","volume":"59","author":"V Jotwani","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/00002030-200206140-00008","article-title":"Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study","volume":"16","author":"RT Schooley","year":"2002","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"M Fisher","year":"2009","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0120705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T03:30:59Z","timestamp":1717817459000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0120705"}},"subtitle":[],"editor":[{"given":"Mark","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,30]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0120705","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,30]]}}}